Quince Therapeutics, Inc.
QNCX
Positions held
Your positionsQNCX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $35.28M | Enterprise value | $57.69M | Trailing P/E | — | Forward P/E | -7.41 |
| PEG | — | Price / book | -1.00 | Beta | 1.33 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -1.5% | ROA | -31.5% | Debt / equity | — |
| Current ratio | 14.52 | Free cash flow | -$25.75M | Analyst recommendation | strong_buy | Mean target | $75.43 |
| 52w high | $910.00 | 52w low | $15.10 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$75.5M | $35.9M | -$39.5M | -$13.4M | -$16.0M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$22.1M | -$11.1M | -$16.2M | -$11.4M | -$9.9M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$84.0M | -$56.8M | -$31.4M | -$51.7M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$50.4M | -$36.2M | -$27.1M | -$51.2M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Quince Therapeutics Renames as IRulya Therapeutics, Advances Pulmonary Drug Development
2026-10-09 · Quince Therapeutics Changes Name to IRulya Therapeutics
2026-10-09 · Raymond James Initiates Quince Therapeutics at Outperform With $72 Price Target
2026-09-24 · CoreWeave upgraded, Etsy downgraded: Wall Street's top analyst calls
2026-09-22 · Netflix downgraded, SanDisk initiated: Wall Street's top analyst calls
2026-09-03 · Quince Therapeutics to Participate in September 2026 Investor Conferences
2026-08-21 · Craig-Hallum Initiates Quince Therapeutics at Buy With $68 Price Target
2026-08-14 · Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Price (daily)
Full chart · RSI · MACD · patterns